Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 4;85:104294. doi: 10.1016/j.ebiom.2022.104294

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Higher antibody avidity upon heterologous ChAd-BNT compared to homologous BNT-BNT vaccination. Antibody avidity of a subcohort (n = 12) from study center Munich after heterologous ChAd-BNT and homologous BNT-BNT vaccination. „Early after #2“ refers to on average (median) 13-15 days after secondary BNT vaccination. „Late after #2“ refers to on average (median) 98 and 110 days after second vaccination. Bars represent group medians, whiskers interquartile range. For inter-group statistics concerning one time point Mann-Whitney test was used. Over-time comparison within one group was done by Friedman test. A detailed description of the data can be found in Supplemental Table for Figure 3.